Novel Herbal Therapy For Men At High Risk Of Prostate Cancer Well-Tolerated In Phase I Trial

[Why Syzygy]

http://www.sciencedaily.com/releases/2009/05/090522154508.htm

ScienceDaily (May 25, 2009) — Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

The new findings, led by researchers from the Center for Holistic Urology at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia, are published in the current issue of the Journal of the Society for Integrative Oncology.

In the study, 23 men ages 40-75 years-old who were diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) at biopsy, lesions that indicate an increased risk of developing prostate cancer, were admitted into this prospective clinical trial, in order to determine the safety and tolerability of Zyflamend when administered orally for 18-months, either alone or along with various dietary supplements.

"Since we know that men with HGPIN have an increased risk for developing prostate cancer, new strategies formulated to decrease cancer risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial for these men," said Aaron E. Katz, M.D., senior author of the study. He is associate professor of urology at Columbia University College of Physicians and Surgeons, director of the Center of Holistic Urology at Columbia University Medical Center and a urologist at NewYork-Presbyterian/Columbia.

Basic science studies have indicated that Zyflamend may have an anti-inflammatory mechanism of action and the agent has been shown to decrease prostate cancer proliferation in cell culture. (...)

http://www.mskcc.org/mskcc/html/69429.cfm

Clinical Summary

Zyflamend is an herbal extract of ten different herbs (1). It is promoted as having anti-inflammatory and antiaging properties. Supporters claim that the beneficial effects of Zyflamend are due to the constituents, many of which reduce inflammation by decreasing cyclooxygenase-2 (COX-2) activity. In vitro studies showed that Zyflamend inhibits COX-1 and COX-2 enzymes, induces apoptosis (4), and inhibits proliferation (8) of human prostate cancer cells. Zyflamend is being investigated in a Phase I clinical trial involving men with prostatic intraepithelial neoplasia (PIN) (2) (7).

[tabatha]

1. Thanks.

There is more than one way to skin a cat (strange expression) - and those that are the least toxic should be studied and evaluated. Especially, if a herbal extract is more likely to be successful and less likely to pollute water resources.

[KT2000]

2. This is good news!

I would also like to recommend that men have each doctor read their biopsies SLIDES when consulting about the different therapies. A person I know was told he had cancer but when another dr he saw for consultation reviewed the slides - he found atypia - not cancer. This was confirmed by Johns Hopkins.

[BuddhaGirl]

3. Zflamend is a fabulous anti-inflammatory

I have been using it for years...it really works.

Thanks for posting this study!

[Why Syzygy]

4. Thanks for your personal endorsement!

I'm going to consider it for chronic pain.